{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=3", "query": { "intervention": "Irinotecan (Camptosar)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 919, "total_pages": 92, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T07:49:55.446Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05319730", "title": "A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "H2 Receptor Antagonist", "type": "DRUG" }, { "name": "Acetaminophen (or equivalent)", "type": "DRUG" }, { "name": "Dexamethasone (or equivalent)", "type": "DRUG" }, { "name": "Steroid Mouthwash (dexamethasone or equivalent)", "type": "DRUG" }, { "name": "Supportive care measures", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2023-05-16", "completion_date": "2029-04-10", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-09T07:49:55.446Z", "location_count": 5, "location_summary": "Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "East Syracuse", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05319730" }, { "nct_id": "NCT00502567", "title": "A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "AZD2171", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Irinotecan (administered with & without Cetuximab)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2005-01", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2011-07-27", "last_synced_at": "2026-10-09T07:49:55.446Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Detroit, Michigan • Nashville, Tennessee", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00502567" }, { "nct_id": "NCT05592626", "title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Genital Neoplasm, Female", "Urogenital Neoplasms", "Lung Neoplasm", "Neoplasms by Site", "Papillomavirus Infection", "Epstein-Barr Virus Infections", "Carcinoma", "Neoplasms", "Vulvar Neoplasms", "Vulvar Diseases", "Abdominal Neoplasm", "NSCLC (Non-small Cell Lung Cancer)", "Colorectal Cancer" ], "interventions": [ { "name": "STAR0602", "type": "DRUG" }, { "name": "Irinotecan (Camptosar)", "type": "COMBINATION_PRODUCT" }, { "name": "Docetaxel (Taxotere)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Marengo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 366, "start_date": "2023-01-04", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-09T07:49:55.446Z", "location_count": 13, "location_summary": "Sacramento, California • Celebration, Florida • Miami, Florida + 10 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Celebration", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05592626" }, { "nct_id": "NCT02358863", "title": "Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "Docetaxel/Capecitabine", "type": "DRUG" }, { "name": "Cisplatin/Irinotecan", "type": "DRUG" }, { "name": "Cisplatin/Docetaxel", "type": "DRUG" }, { "name": "IRI/EPI", "type": "DRUG" }, { "name": "EPI/Docetaxel", "type": "DRUG" }, { "name": "Irinotecan/Docetaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2015-02", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2018-09-06", "last_synced_at": "2026-10-09T07:49:55.446Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02358863" }, { "nct_id": "NCT04525014", "title": "RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumor, Recurrent", "Brain Tumor, Pediatric", "Central Nervous System Neoplasms", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 2, "start_date": "2023-01-26", "completion_date": "2024-07-29", "has_results": false, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-10-09T07:49:55.446Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04525014" }, { "nct_id": "NCT00024284", "title": "Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": null, "start_date": "2001-06", "completion_date": "2003-12", "has_results": false, "last_update_posted_date": "2013-04-05", "last_synced_at": "2026-10-09T07:49:55.446Z", "location_count": 6, "location_summary": "Tucson, Arizona • Washington D.C., District of Columbia • St Louis, Missouri + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024284" }, { "nct_id": "NCT05694715", "title": "Combination Therapy in Cancers With Mutations in DNA Repair Genes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumor", "BRCA1 Mutation", "BRCA2 Mutation", "ATM Gene Mutation", "PALB2 Gene Mutation" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-05-23", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-09T07:49:55.446Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05694715" }, { "nct_id": "NCT03632135", "title": "Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "ChemoID assay", "type": "DIAGNOSTIC_TEST" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "Cordgenics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2018-05-20", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-04-15", "last_synced_at": "2026-10-09T07:49:55.446Z", "location_count": 13, "location_summary": "Los Angeles, California • New Orleans, Louisiana • Scarborough, Maine + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT03632135" }, { "nct_id": "NCT01313884", "title": "Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Cancer", "Ewing's Sarcoma" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 3, "start_date": "2011-05", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-10-09T07:49:55.446Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01313884" }, { "nct_id": "NCT01888978", "title": "Molecularly Tailored Therapy for Pancreas Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gem-OX", "type": "DRUG" }, { "name": "Gem-5FU", "type": "DRUG" }, { "name": "Gem-Tax", "type": "DRUG" }, { "name": "Modified FOLFOX-6", "type": "DRUG" }, { "name": "Ox-Tax", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Tax-Iri", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2012-12", "completion_date": "2018-01-24", "has_results": false, "last_update_posted_date": "2018-04-09", "last_synced_at": "2026-10-09T07:49:55.446Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Olney, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Olney", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01888978" } ] }